SCHEMBL34470137

SCHEMBL34470137

CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)[C@@H](C)O)C(C)C)C(C)C

nearest known ligand 0.67

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ KISS1R Q969F8 12/20 0.67
▸ IL23R Q5VWK5 1/20 0.66
▸ C5AR1 P21730 2/20 0.61
▸ NPY1R P25929 1/20 0.60
▸ NPY2R P49146 1/20 0.60
▸ NPY4R P50391 1/20 0.60
▸ NPY5R Q15761 1/20 0.60
▸ CTNNB1 P35222 2/20 0.56
▸ CXCR4 P61073 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29973644 0.93 KISS1R (0.66) KISS1RIL23RC5AR1NPY1RNPY2R
SCHEMBL30268594 0.92 IL23R (0.66) KISS1RIL23RC5AR1NPY1RNPY2R
SCHEMBL29598567 0.92 KISS1R (0.65) KISS1RIL23RC5AR1
SCHEMBL31468796 0.91 KISS1R (0.64) KISS1RIL23RC5AR1NPY1RNPY2R
SCHEMBL31307225 0.91 IL23R (0.65) KISS1RIL23RC5AR1NPY1RNPY2R
SCHEMBL30423542 0.91 NPY1R (0.66) KISS1RC5AR1NPY1RNPY2RNPY4R
SCHEMBL31332280 0.90 KISS1R (0.64) KISS1RIL23RC5AR1
SCHEMBL5710723 0.90 CXCR4 (0.66) KISS1RIL23RC5AR1NPY1RNPY2R
SCHEMBL31430442 0.89 C5AR1 (0.62) KISS1RIL23RC5AR1
SCHEMBL31410855 0.89 KISS1R (0.65) KISS1RIL23RC5AR1NPY1RNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090251-A1 METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION PROLETARIAT THERAPEUTICS, INC. (US) 2026-04-30 — — WO disclosed
Send feedback